Cargando…

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

The aim of this study was to evaluate, in a prospective study, the predictive role of p53 status analysed at four different levels in identifying the response to preoperative radiotherapy in rectal adenocarcinoma. Before treatment, 70 patients were staged and endoscopic forceps biopsies from the tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Crapez, E, Bibeau, F, Thézenas, S, Ychou, M, Simony-Lafontaine, J, Thirion, A, Azria, D, Grenier, J, Senesse, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361816/ https://www.ncbi.nlm.nih.gov/pubmed/15956964 http://dx.doi.org/10.1038/sj.bjc.6602622

Ejemplares similares

Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer
por: Azria, David, et al.
Publicado: (2005)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
por: Samalin, E, et al.
Publicado: (2014)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
por: Jacot, William, et al.
Publicado: (2011)

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2009)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Trends with neoadjuvant radiotherapy and clinical staging for those with rectal malignancies
por: Reddy, Sanjay S, et al.
Publicado: (2017)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol
por: Mens, D. M., et al.
Publicado: (2023)

Second primary malignancy risk after radiotherapy in rectal cancer survivors
por: Wang, Ti-Hao, et al.
Publicado: (2018)

Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study
por: Chen, Nan, et al.
Publicado: (2022)

Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed
por: Kunneman, M, et al.
Publicado: (2015)

Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences
por: Pieterse, A H, et al.
Publicado: (2007)

Radiomics for predicting perineural invasion status in rectal cancer
por: Li, Mou, et al.
Publicado: (2021)

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
por: Bibeau, Frédéric, et al.
Publicado: (2006)

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
por: Bordeau, Karl, et al.
Publicado: (2023)

Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial
por: Nilsson, Per J, et al.
Publicado: (2013)

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society
por: Siegel, Robert, et al.
Publicado: (2009)

Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors
por: Simony-Lafontaine, J, et al.
Publicado: (2000)

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
por: Loi, S, et al.
Publicado: (2005)

Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study
por: Bordeau, Karl, et al.
Publicado: (2022)

Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer
por: Gao, Shu-Quan, et al.
Publicado: (2021)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial
por: Lemanski, Claire, et al.
Publicado: (2013)

Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study
por: Michalet, Morgan, et al.
Publicado: (2022)

WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients
por: Zhang, Hong, et al.
Publicado: (2012)

Nomogram to predict ypN status after chemoradiation in patients with locally advanced rectal cancer
por: Jwa, E, et al.
Publicado: (2014)

Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer
por: Craven, I, et al.
Publicado: (2007)

Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
por: Koeberle, D, et al.
Publicado: (2008)

Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)
por: Wang, Yaqi, et al.
Publicado: (2022)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Peak Oxygen Uptake Responses to Training in Obese Adolescents: A Multilevel Allometric Framework to Partition the Influence of Body Size and Maturity Status
por: Carvalho, Humberto M., et al.
Publicado: (2013)

Global status of research on radiotherapy for rectal cancer: A bibliometric and visual analysis
por: Xiao, Yafei, et al.
Publicado: (2022)

Does setup on rectal wall improve rectal cancer boost radiotherapy?
por: Kleijnen, Jean-Paul J. E., et al.
Publicado: (2018)

Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases
por: Del Rio, Maguy, et al.
Publicado: (2013)

Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial
por: Combs, Stephanie E, et al.
Publicado: (2012)

CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II
por: Voelter, V, et al.
Publicado: (2006)

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases
por: Braccini, Antoine-Laurent, et al.
Publicado: (2013)

Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer
por: Corrò, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2e2r535pok6fbdbig6c1jadseb